메뉴 건너뛰기




Volumn 32, Issue 16, 2011, Pages

Novel oral anticoagulants: Focus on stroke prevention and treatment of venous thrombo-embolism

Author keywords

Apixaban; Atrial fibrillation; AVERROES; Dabigatran etexilate; Edoxaban; ENGAGE TIMI 48; Novel anticoagulants; RE LY; Rivaroxaban; ROCKET AF

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

EID: 80051834654     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr052     Document Type: Review
Times cited : (60)

References (69)
  • 1
    • 33644851056 scopus 로고    scopus 로고
    • Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications
    • Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113:722-731.
    • (2006) Circulation , vol.113 , pp. 722-731
    • Steffel, J.1    Luscher, T.F.2    Tanner, F.C.3
  • 3
    • 4644230820 scopus 로고    scopus 로고
    • The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • DOI 10.1378/chest.126.3-suppl.204S
    • Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):204S-233S. (Pubitemid 39297955)
    • (2004) Chest , vol.126 , Issue.3 SUPPL.
    • Ansell, J.1    Hirsh, J.2    Poller, L.3    Bussey, H.4    Jacobson, A.5    Hijlek, E.6
  • 4
    • 34347394385 scopus 로고    scopus 로고
    • Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867. (Pubitemid 351650486)
    • (2007) Annals of Internal Medicine , vol.146 , Issue.12 , pp. 857-867
    • Hart, R.G.1    Pearce, L.A.2    Aguilar, M.I.3
  • 6
    • 0142135442 scopus 로고    scopus 로고
    • Warfarin and other coumarin derivatives: Pharmacokinetics, pharmacodynamics, and drug interactions
    • DOI 10.1055/s-2003-44457
    • Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3:221-230. (Pubitemid 37280710)
    • (2003) Seminars in Vascular Medicine , vol.3 , Issue.3 , pp. 221-230
    • Wittkowsky, A.K.1
  • 7
    • 0023067985 scopus 로고
    • Warfarin metabolism and drug-drug interactions
    • O'Reilly RA. Warfarin metabolism and drug-drug interactions. Adv Exp Med Biol 1987;214:205-212.
    • (1987) Adv Exp Med Biol , vol.214 , pp. 205-212
    • O'Reilly, R.A.1
  • 8
    • 45949108549 scopus 로고    scopus 로고
    • Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
    • DOI 10.1378/chest.08-0652
    • Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl. 6):110S-112S. (Pubitemid 351892962)
    • (2008) Chest , vol.133 , Issue.6 SUPPL. 6
    • Hirsh, J.1    Guyatt, G.2    Albers, G.W.3    Harrington, R.4    Schunemann, H.J.5
  • 10
    • 68349093744 scopus 로고    scopus 로고
    • Novel anticoagulants in clinical development: Focus on factor Xa and direct thrombin inhibitors
    • Steffel J, Luscher TF. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown, MD) 2009;10: 616-623.
    • (2009) J Cardiovasc Med (Hagerstown, MD) , vol.10 , pp. 616-623
    • Steffel, J.1    Luscher, T.F.2
  • 11
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • DOI 10.1111/j.1365-2125.2007.02899.x
    • Stangier J, Rathgen K, Stahle H, Gansser D, RothW. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. (Pubitemid 47283865)
    • (2007) British Journal of Clinical Pharmacology , vol.64 , Issue.3 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stahle, H.3    Gansser, D.4    Roth, W.5
  • 12
    • 41949116970 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate
    • DOI 10.2165/00003088-200847050-00001
    • Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-295. (Pubitemid 351508116)
    • (2008) Clinical Pharmacokinetics , vol.47 , Issue.5 , pp. 285-295
    • Stangier, J.1
  • 15
    • 77949312944 scopus 로고    scopus 로고
    • Drug-induced liver injury in humans: The case of ximelagatran
    • Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-418.
    • (2010) Handb Exp Pharmacol , vol.196 , pp. 407-418
    • Keisu, M.1    Andersson, T.B.2
  • 16
    • 78349313002 scopus 로고    scopus 로고
    • Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial
    • Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-1163
    • (2010) Lancet Neurol , vol.9 , pp. 1157-1163
    • Diener, H.C.1    Connolly, S.J.2    Ezekowitz, M.D.3    Wallentin, L.4    Reilly, P.A.5    Yang, S.6    Xavier, D.7    Di Pasquale, G.8    Yusuf, S.9
  • 22
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
    • DOI 10.1016/S0140-6736(07)61445-7, PII S0140673607614457
    • Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370: 949-956. (Pubitemid 47393577)
    • (2007) Lancet , vol.370 , Issue.9591 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3    Kurth, A.A.4    Van Dijk, C.N.5    Frostick, S.P.6    Prins, M.H.7    Hettiarachchi, R.8    Hantel, S.9    Schnee, J.10    Buller, H.R.11
  • 24
    • 79953836474 scopus 로고    scopus 로고
    • Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, noninferiority trial
    • [Epub ahead of print]
    • Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, noninferiority trial. Thromb Haemost 2011;105. [Epub ahead of print].
    • (2011) Thromb Haemost , pp. 105
    • Eriksson, B.I.1    Dahl, O.E.2    Huo, M.H.3    Kurth, A.A.4    Hantel, S.5    Hermansson, K.6    Schnee, J.M.7    Friedman, R.J.8
  • 29
    • 44449100797 scopus 로고    scopus 로고
    • Idraparinux: Review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
    • DOI 10.1517/13543784.17.5.773
    • Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 2008;17:773-777. (Pubitemid 351843619)
    • (2008) Expert Opinion on Investigational Drugs , vol.17 , Issue.5 , pp. 773-777
    • Prandoni, P.1    Tormene, D.2    Perlati, M.3    Brandolin, B.4    Spiezia, L.5
  • 30
    • 70449598269 scopus 로고    scopus 로고
    • Development of idraparinux and idrabiotaparinux for anticoagulant therapy
    • Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102:811-815.
    • (2009) Thromb Haemost , vol.102 , pp. 811-815
    • Harenberg, J.1
  • 31
    • 77952703086 scopus 로고    scopus 로고
    • Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion
    • Paty I, Trellu M, Destors JM, Cortez P, Boelle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8:722-729.
    • (2010) J Thromb Haemost , vol.8 , pp. 722-729
    • Paty, I.1    Trellu, M.2    Destors, J.M.3    Cortez, P.4    Boelle, E.5    Sanderink, G.6
  • 32
    • 84857100961 scopus 로고    scopus 로고
    • NCT00580216 at 1st November 2010
    • NCT00580216 at http://www.clinicaltrials.gov/(1st November 2010).
  • 33
    • 78650941964 scopus 로고    scopus 로고
    • Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis
    • Equinox investigators
    • Equinox investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2010;9:92-99.
    • (2010) J Thromb Haemost , vol.9 , pp. 92-99
  • 40
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
    • Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3    Eriksson, B.I.4    Mouret, P.5    Muntz, J.6    Soglian, A.G.7    Pap, A.F.8    Misselwitz, F.9    Haas, S.10
  • 42
    • 78650619315 scopus 로고    scopus 로고
    • Oral rivaroxaban for symptomatic venous thromboembolism
    • The EINSTEIN Investigators
    • The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510
    • (2010) N Engl J Med , vol.363 , pp. 2499-2510
  • 46
    • 64849114048 scopus 로고    scopus 로고
    • Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
    • Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009;101:780-782.
    • (2009) Thromb Haemost , vol.101 , pp. 780-782
    • Jiang, X.1    Crain, E.J.2    Luettgen, J.M.3    Schumacher, W.A.4    Wong, P.C.5
  • 50
    • 77649113258 scopus 로고    scopus 로고
    • Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
    • Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-815.
    • (2010) Lancet , vol.375 , pp. 807-815
    • Lassen, M.R.1    Raskob, G.E.2    Gallus, A.3    Pineo, G.4    Chen, D.5    Hornick, P.6
  • 51
    • 79851483966 scopus 로고    scopus 로고
    • Apixaban versus enoxaparin in patients with total knee arthroplasty A meta-analysis of randomised trials
    • Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 2010;105:245-253.
    • (2010) Thromb Haemost , vol.105 , pp. 245-253
    • Huang, J.1    Cao, Y.2    Liao, C.3    Wu, L.4    Gao, F.5
  • 53
    • 47649098524 scopus 로고    scopus 로고
    • Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
    • DOI 10.1111/j.1538-7836.2008.03054.x
    • Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-1318. (Pubitemid 352016310)
    • (2008) Journal of Thrombosis and Haemostasis , vol.6 , Issue.8 , pp. 1313-1318
    • Buller, H.1    Deitchman, D.2    Prins, M.3    Segers, A.4
  • 55
    • 77953787643 scopus 로고    scopus 로고
    • Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers
    • Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
    • (2010) J Clin Pharmacol , vol.50 , pp. 743-753
    • Ogata, K.1    Mendell-Harary, J.2    Tachibana, M.3    Masumoto, H.4    Oguma, T.5    Kojima, M.6    Kunitada, S.7
  • 57
    • 77957932391 scopus 로고    scopus 로고
    • Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)
    • Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641.
    • (2010) Am Heart J , vol.160 , pp. 635-641
    • Ruff, C.T.1    Giugliano, R.P.2    Antman, E.M.3    Crugnale, S.E.4    Bocanegra, T.5    Mercuri, M.6    Hanyok, J.7    Patel, I.8    Shi, M.9    Salazar, D.10    McCabe, C.H.11    Braunwald, E.12
  • 58
    • 60549096887 scopus 로고    scopus 로고
    • Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated
    • Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009;40:235-240.
    • (2009) Stroke , vol.40 , pp. 235-240
    • Gladstone, D.J.1    Bui, E.2    Fang, J.3    Laupacis, A.4    Lindsay, M.P.5    Tu, J.V.6    Silver, F.L.7    Kapral, M.K.8
  • 62
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-1127.
    • (2010) Thromb Haemost , vol.103 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3    Liesenfeld, K.H.4    Wienen, W.5    Feuring, M.6    Clemens, A.7
  • 65
    • 78649736882 scopus 로고    scopus 로고
    • Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
    • Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104:1263-1271.
    • (2010) Thromb Haemost , vol.104 , pp. 1263-1271
    • Barrett, Y.C.1    Wang, Z.2    Frost, C.3    Shenker, A.4
  • 66
    • 63149098718 scopus 로고    scopus 로고
    • Laboratory monitoring of anticoagulation: Where do we stand?
    • Tripodi A, van den Besselaar A. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost 2009;35:34-41.
    • (2009) Semin Thromb Hemost , vol.35 , pp. 34-41
    • Tripodi, A.1    Van Den Besselaar, A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.